IRPCM

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== Chemotherapy of Mycoplasma Infections ======
  * Team Leader: Florence Tardy (France)

  * Vision of the IRPCM chemotherapy group:
    * Ascertain and reduce antimicrobial resistance levels in mollicutes to protect global human and animals for the future
    * Coordinating international agreed standards for MIC of mollicute species
    * Mapping global resistance of mollicutes of human and veterinary importance
    * Reducing unnecessary use of antimicrobials and promoting good stewardship
    * Understanding the molecular mechanisms of resistance
    * Evaluation of new and alternative agents

  * Current Goals:
    * To standardize veterinary mycoplasma antimicrobial sensitivity testing, including control strains and methodology like it was done for human mycoplasmas.
    * To continue work on molecular determinants of antimicrobial resistance
    * Identifying breakpoints
    * Epidemiological surveillance
    * Monitoring of antimicrobial resistance
    * Development of the molecular assay to track antimicrobial resistance in the real-time
    * Molecular typing of strains with different susceptibility
    * Evaluation of new and alternative chemotherapeutic agents